StockData
Entera Bio Ltd. logo

Entera Bio Ltd. (ENTX) stock

ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$3.26+0.26 (+8.67%)

Close on Nov 18, 2026Market cap $564.44MP/E –Yield –

Entera Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Entera Bio's revenue for the twelve months ending Jun 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was $42.00K, down 76.8% from the year before. The highest annual figure on record is $571.00K in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$42.00K-76.8%
FY2024Dec 31, 2024$181.00K–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$134.00K-76.5%
FY2021Dec 31, 2021$571.00K+56.4%
FY2020Dec 31, 2020$365.00K+54.7%
FY2019Dec 31, 2019$236.00K-52.8%
FY2018Dec 31, 2018$500.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0-100.0%
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0-100.0%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$42.00K–
Q4 FY2024Dec 31, 2024$82.00K–
Q3 FY2024Sep 30, 2024$42.00K–
Q2 FY2024Jun 30, 2024$57.00K–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0-100.0%
Q3 FY2023Sep 30, 2023$0-100.0%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$0-100.0%
Q4 FY2022Dec 31, 2022$14.00K-91.5%
Q3 FY2022Sep 30, 2022$8.00K-94.3%
Q2 FY2022Jun 30, 2022$44.00K-59.6%
Q1 FY2022Mar 31, 2022$68.00K-56.7%
Q4 FY2021Dec 31, 2021$165.00K+217.3%
Q3 FY2021Sep 30, 2021$140.00K+89.2%
Q2 FY2021Jun 30, 2021$109.00K–
Q1 FY2021Mar 31, 2021$157.00K–
Q2 FY2020Jun 30, 2020$52.00K–
Q2 FY2019Jun 30, 2019$74.00K–

More Entera Bio figures

See a number that looks wrong?